Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of 4th Dose COVID-19 Vaccines (AZ, Pfizer, Clover)
NCT05470803Phase 3Unknown
- Sponsor
- Instituto D’Or de Pesquisa e Ensino
- Start
- Aug 2022
- Primary completion
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of SCB-2019 in coronavirus disease 2019 (COVID-19) (10 cohorts), sponsored by Instituto D’Or de Pesquisa e Ensino. Primary endpoint: Immunogenicity at 28 days. Status: unknown.
02
Drugs
SCB-2019
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05470803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470803.